Compass Pathways ($CMPS) released an interim readout from their Phase 3 trial of Psilocybin (COMP360) for treatment resistant depression (TRD).

The data was positive and highly anticipated by the psychedelic community, but the stock dropped 50% on June 23rd. Brom Rector and Sam Tabone of XEIA Venture Partners react and comment in this emergency podcast.

We discuss:

(0:00) - what did the Compass Pathways data readout actually say

(12:00) - putting the Compass trial results into context vs SSRIs, Lexapro, Spravato and Ketamine

(19:00) - why Compass crashed

(24:00) - will Comp360 get FDA approval?

(26:00) - will COMP360 be commercially successful?

(30:00) - price targets for Compass Pathways $CMPS

(35:00) - will Compass get acquired?

(40:00) - are we bullish or bearish on Compass?

Learn more about Brom, Sam and XEIA at www.xeiavp.com